5Y Capital

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, which supports advancements in synthetic biology. Situated within the prestigious Cambridge cluster of high-tech and life science organizations, Evonetix aims to revolutionize DNA synthesis through novel techniques that enhance efficiency and capability. The team at Evonetix comprises experienced professionals from various scientific and engineering disciplines, bringing together a wealth of knowledge to drive the commercialization of their technology.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, which supports advancements in synthetic biology. Situated within the prestigious Cambridge cluster of high-tech and life science organizations, Evonetix aims to revolutionize DNA synthesis through novel techniques that enhance efficiency and capability. The team at Evonetix comprises experienced professionals from various scientific and engineering disciplines, bringing together a wealth of knowledge to drive the commercialization of their technology.

Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.

InSilixa, Inc., headquartered in Sunnyvale, CA, is a multidisciplinary, highly motivated and highly technical team comprised of industry veterans with diverse backgrounds in semiconductor, biotechnology, medicine, and informatics. Founded in 2012, InSilixa is driven by the quest to democratize and drive down the cost of molecular diagnostics worldwide by leveraging its proprietary semiconductor-based CMOS biochip technology. To that end, the company is developing point-of-care (PoC) and near patient platforms for the delivery of low cost, high-performance, and mass-deployable solutions for DNA and protein-based diagnostic testing.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.